Asian Tech Press -- CanSinoBIO's inhaled COVID-19 vaccine Ad5-nCo, also known as Convidecia, has proven to have good safety in phase 1 clinical trial, according to a recent research published in The Lancet.

The preliminary report of Phase 1 clinical trial of the aerosolised inhalation of adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV), jointly developed by Chen Wei's team at the Beijing Institute of Biotechnology — part of the Academy of Military Medical Sciences and CanSino Biologics, was published on July 26 in The Lancet Infectious Diseases.

It is the world's first published clinical data on an aerosol COVID-19 vaccine.

TThe results showed that the aerosol inhalation of Ad5-nCoV was well tolerated and did not cause any serious adverse events associated with the vaccine.

One dose of aerosolized Ad5-nCoV was equivalent to one-fifth of a single dose of intramuscular injection. And two doses of aerosolized inhalation of Ad5-nCoV elicited a neutralizing antibody response to SARS-CoV-2 neocoronavirus similar to that of one dose of this vaccine administered intramuscularly.

On the other hand, an aerosolised booster vaccination at day 28 after intramuscular injection of Ad5-nCoV, induced strong responses of anti-SARS-CoV-2 spike receptor IgG antibodies and SARS-CoV-2 neutralising antibodies.

It is known that the vaccine has been conditionally approved for marketing by China's National Medical Products Administration (NMPA) on February 25, and becoming the first home-made adenovirus vector COVID-19 vaccine to be approved in China.

The vaccine is administered by a single dose and can be transported and stored at 2-8°C.

At present, Convidecia has been approved for emergency use in Mexico, Pakistan, Hungary, Chile, Argentina and other countries.